Stepwise deescalation of #DAPT in #ACS pts undergoing #PCI with #DCB is noninferior to 12mo DAPT CAGE FREE 2 trial #EuroPCR2024 #ticagrelor Davide Capodanno Dr Roxana Mehran John Mandrola, MD Felice Gragnano Davide Cao SABOURETCardiologist Michael Savage David L. Fischman Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Erin D. Michos, M.D.

New REVIVED data. More baseline HF symptoms than key HFrEF trials (eg DAPA-HF, PARADIGM-HF). KCCQ-OSS 62. Severe symptomatic HFrEF (despite NYHA II classification). Short term (not sustained) improvement in QoL (open label trial). JACC HF DOI: 10.1016/j.jchf.2024.03.010

Wow. Even in an open label trial, PCI in the “perfect” patient (amenable anatomy + viability) did not result in QOL improvements at one year over simple tablets.

REVIVED continues to shock the cardiology community

Link jacc.org/doi/10.1016/j.…

In ORBITA-STAR, angina verification with an ischaemic stimulus powerfully predicted response to PCI. #EuroPCR2024

Perhaps we have been too focused on treatment when the problem always lay in the diagnosis! Published today in #JACC jacc.org/doi/10.1016/j.… Rasha Al-Lamee

There are three major late-breaking trials presented this year at #EuroPCR (May 15, 8.30-10.00 AM CEST).

The first trial is called REC-CAGEFREE II. It is the first randomized study of antiplatelet monotherapy after PCI with drug-coated balloons. It will test a stepwise regimen

#EuroPCR 2024 is fast approaching and to prepare for the Course, this year we have prepared the #EIJchallenge , which will put your knowledge of the journal and cardiovascular medicine to the test.

It will unfold in 2 parts: an online challenge on social media (Level 1) and then

Marta Bande presenting where challenges meet opportunities

#GreekWomeninCardiology Boston Scientific

Things you read in JACC Journals while preparing for a talk... 🏹🎯🇨🇾

Great recruitment strategy! Mamas A. Mamas Ekaterini Lambrinou💙 Vass Vassiliou Dr Anastasia Mihailidou FAHA FCSANZ FESC

Prof. Janina Stępińska advocates for targeted education among #women to address critical delays in reporting #cardiovascular #symptoms and seeking #timely #interventions .

prev-interv.com

Marta Kaluzna-Oleksy Prof. Izabella Uchmanowicz, RN, PhD, FESC, FHFA Michal Hawranek Bartosz Hudzik MD PhD FESC FACC Anna

I am passionate about neutral studies, but only when their results are true negatives, not false negatives due to low statistical power. I particularly appreciate them when they eliminate drugs with seemingly routine indications but are actually poorly supported by literature or

My TCTMD video Beyond the Data: ORBITA-COSMIC with Rasha Al-Lamee and michael foley ➡️ tctmd.com/videos/beyond-…
💡Does this trial bring us closer to understanding mechanisms
💡 how do we define refractory angina
💡will CSO work for microvascular disease?

🔥The future of EAPCI is in our hands🔥

Last 4 days to vote, don’t miss the chance
Marta Kaluzna-Oleksy Bartosz Hudzik MD PhD FESC FACC Mariusz Tomaniak Zenon Huczek Mariusz Polakowski Grupa American Heart of Poland Marek Gierlotka Piotr Buszman MD, PhD Kamil Bujak Marta Bujak Eric Van Belle Martine Gilard rui teles

In this new state-of-the-art article, the authors summarize the rationale for renal denervation, review the available evidence, provide recommendations for a safe procedure, and discuss the role of renal denervation in current guidelines and clinical practice.

1/
ORBITA-COSMIC
Placebo-controlled trial of Coronary sinus reducer (CSR) for refractory angina

Trial continues trend of several LBCTs (late breaking clinical TRENDS) that failed to win on PEP but were ‘salvaged’ by a positive SEP or a subgroup (RELIEVE-HF, AEGIS-II, EMPACT-MI)

“OMT “ in #PREVENT : LDL at 88 vs 93 mg/dL …need to see in details all the medical strategies. #ACC24

Results (look at medical strategies and absolute numbers of clinically relevant events) #ACC24

Percutaneous coronary intervention for non-obstructive vulnerable plaques. #ACC24 #PREVENT study. Few events in both groups. Instead of #PCI , why not to choose an intensive #LLT strategy ? With adequate #DAPT or #SAPT . thelancet.com/journals/lance…

Discontinuing renin–angiotensin system inhibitors before non-cardiac surgery did not reduce myocardial injury. Read the SPACE trial paper.
doi.org/10.1093/eurhea…
#surgery #hypertension #cardiotwitter European Society of Cardiology Journals European Society of Cardiology

Do most pts w/ #ACS can safely stop #aspirin 1️⃣mo post #PCI ? Importantly, 70% of pts had 1️⃣vessel #CAD & 88% were Chinese #DAPT #ticagrelor #bleeding #HBR #ACC24 Davide Capodanno Marco Valgimigli Dr Roxana Mehran Professor Vijay Kunadian Giuseppe Biondi-Zoccai MIЯVΛƬ #IC Felice Gragnano Davide Cao Mamas A. Mamas

#Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 #RCT #ACC24 jamanetwork.com/journals/jamac…